Welcome to our dedicated page for Hca Healthcare news (Ticker: HCA), a resource for investors and traders seeking the latest updates and insights on Hca Healthcare stock.
HCA Healthcare operates a healthcare services network built around acute-care hospitals and ambulatory sites of care in the United States and the United Kingdom. Company news commonly addresses hospital operating trends, same-facility admissions, emergency room visits, inpatient and outpatient surgeries, revenue per equivalent admission and quarterly financial results.
Updates also cover capital allocation and financing activity, including dividends, share repurchase authorizations, commercial paper, senior notes issued by HCA Inc., and debt redemptions. Other recurring developments include hospital quality recognition, investor conference presentations, enterprise marketing and corporate affairs leadership, and the role of surgery centers, freestanding ERs, urgent care centers and physician clinics within HCA's ambulatory care platform.
HCA Healthcare, Inc. (NYSE: HCA) will host its 2Q Earnings Release Call on July 22, 2022, at 8:00 AM Central (9:00 AM Eastern). Investors can listen live via audio on the internet. The event can be accessed through the HCA Healthcare investor relations page. An archived version of the call will also be available for those unable to attend live. This call is expected to provide insights into HCA's quarterly performance, including earnings and operational updates.
McKesson Corporation and HCA Healthcare have announced a joint venture to combine their oncology research arms, US Oncology Research and Sarah Cannon Research Institute, enhancing clinical trial access and drug development. This venture aims to expand oncology research, streamline trial matching for patients, and improve access, particularly for underserved communities. McKesson will hold 51% ownership, with the joint venture expected to close in 2022. Financial details remain undisclosed, and the agreement is subject to regulatory approvals.
McKesson Corporation and HCA Healthcare have announced a joint venture to combine their oncology research efforts, enhancing clinical trials and treatment options for cancer patients. The venture will merge McKesson’s US Oncology Research with HCA’s Sarah Cannon Research Institute, aiming to improve access and accelerate cancer drug development, especially in underserved communities. McKesson will hold a 51% stake and operating control. The deal is expected to close in 2022, pending regulatory approval and customary conditions.
HCA Healthcare announced the opening of a new Galen College of Nursing campus in Asheville, North Carolina, enhancing nursing education amid a national shortage. The new campus, opening in late September, will be the eighth location for Galen since joining HCA in 2020, expanding total enrollment to approximately 10,000 students. The U.S. Bureau of Labor Statistics projects 194,500 annual nursing job openings for the next decade, highlighting the growing need for trained nurses. HCA aims to leverage this partnership to improve patient care and nursing education.
HCA Healthcare has announced a three-year, $1.38 million grant to the Girl Scouts of the USA for youth mental wellness workshops. This initiative aims to develop curricula focusing on mental health for girls in grades 4-12, with workshops launching in summer 2023. The grant is part of the Healthier Tomorrow Fund, which has committed $4.5 million since 2021 to address community health needs. HCA Healthcare emphasizes the importance of mental health, supporting various initiatives including the Nurse Care program for caregivers.
HCA Healthcare has appointed Keith Zimmerman as the new president of its MidAmerica Division, effective June 13, following the retirement of Mel Lagarde. Zimmerman, a 31-year healthcare veteran and former CEO of Medical City Arlington, will oversee seven hospitals and various care sites in the Kansas City area. During Lagarde's 40-year tenure, he contributed significantly to HCA's success. HCA operates 182 hospitals and approximately 2,300 ambulatory sites, emphasizing patient-focused care and clinical advancements.
HCA Healthcare (NYSE: HCA) is scheduled to present at two healthcare conferences in May 2022. The first presentation will be on May 11, 2022, at 8:00 am PDT during the BofA Securities 2022 Healthcare Conference in Las Vegas, NV. The second presentation is set for May 18, 2022, at 9:30 am EDT, at the RBC Capital Markets Global Healthcare Conference in New York, NY. Investors can access live audio webcasts and presentation materials on the company’s website, with details subject to change.
Valify, a healthcare cost management company based in Frisco, Texas, has been named “Company of the Year” by CIOReview in the 50 most promising healthcare solutions category. Valify utilizes a proprietary technology platform to analyze healthcare spending, helping hospitals reduce operational costs and financial risk. The company, acquired by HCA Healthcare, manages over $600 billion in categorized spend across 1,300 service categories, offering end-to-end cost management solutions to thousands of hospitals.
HCA Healthcare (NYSE: HCA) announced a donation of $1.5 million to Florida International University’s Nursing College to address the national nursing shortage. The funding will support faculty expansion and scholarships, contributing to HCA's broader $10 million commitment over three years aimed at enhancing diversity in healthcare. This partnership reflects HCA's dedication to cultivating a workforce equipped to meet future healthcare challenges, especially as U.S. nursing schools struggle with faculty shortages, having turned away over 80,000 qualified applicants in 2019.
HCA Healthcare reported first-quarter 2022 revenues of $14.945 billion, up from $13.977 billion in Q1 2021. Net income was $1.273 billion or $4.14 per diluted share, down from $1.423 billion. Adjusted EBITDA fell to $2.944 billion from $3.052 billion a year prior. Key metrics showed 2.1% and 5.0% increases in same facility admissions and equivalent admissions, respectively. The company revised its 2022 guidance, lowering revenue expectations to $59.5 to $61.5 billion and net income to $4.950 to $5.340 billion.